Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018
- LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
- Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
- Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://nnw.fm/Diks8). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.
LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.
The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://nnw.fm/Swjx2). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://nnw.fm/q84ZV).
LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.
Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://nnw.fm/bNK6r). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.
The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
- Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
- Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://nnw.fm/Diks8). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.
LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.
The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://nnw.fm/Swjx2). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://nnw.fm/q84ZV).
LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.
Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://nnw.fm/bNK6r). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.
The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
